Literature DB >> 22361472

Human leukocyte antigen-specific antibodies and gamma-interferon stimulate human microvascular and glomerular endothelial cells to produce complement factor C4.

Rizwan Hamer1, Guerman Molostvov, David Lowe, Simon Satchell, Peter Mathieson, Rebecca Ilyas, Daniel A Mitchell, For T Lam, Habib Kashi, Lam Chin Tan, Chris Imray, Simon Fletcher, David Briggs, Nithya Krishnan, Robert Higgins, Daniel Zehnder.   

Abstract

BACKGROUND: The role of the complement system in antibody-mediated rejection has been investigated in relation to circulating complement interacting with renal microvascular endothelium, resulting in the formation of peritubular capillary C4d. However, the possible importance of local complement synthesis is less clear. The aim of this study was to determine whether human vascular endothelium could produce C4 in response to stimulation in vitro.
METHODS: Human microvascular endothelial cells and glomerular endothelial cells were stimulated with endotoxins, cytokines, and human leukocyte antigen-specific antibodies. Synthesis of complement was investigated using western blotting and indirect immunofluorescence. De novo C4 synthesis was confirmed by using C4 small interfering RNA.
RESULTS: Glomerular and microvascular endothelium, both produce C3 and C4 complement protein. Complement synthesis was stimulant-specific-C3 was produced mainly after stimulation with lipopolysaccharide whereas C4 synthesis occurred on treatment with gamma interferon. Culture with human leukocyte antigen-specific antibodies resulted in a significant increase of C4 protein synthesis by both cell lines.
CONCLUSIONS: We have shown for the first time that human microvascular endothelium can be stimulated to synthesize C4 in vitro. The implications of this for clinical transplantation, especially in the context of antibody-mediated rejection, its histological interpretation and as a potential target for therapy would have to be determined by further studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22361472     DOI: 10.1097/TP.0b013e31824b3762

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

Review 1.  Antibody-incompatible kidney transplantation in 2015 and beyond.

Authors:  Rob M Higgins; Sunil Daga; Dan A Mitchell
Journal:  Nephrol Dial Transplant       Date:  2014-12-13       Impact factor: 5.992

2.  Placental C4d deposition is a feature of defective placentation: observations in cases of preeclampsia and miscarriage.

Authors:  Eun Na Kim; Bo Hyun Yoon; Joong Yeup Lee; Doyeong Hwang; Ki Chul Kim; JoonHo Lee; Jae-Yoon Shim; Chong Jai Kim
Journal:  Virchows Arch       Date:  2015-03-28       Impact factor: 4.064

Review 3.  The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection.

Authors:  Kimberly A Thomas; Nicole M Valenzuela; Elaine F Reed
Journal:  Trends Mol Med       Date:  2015-03-20       Impact factor: 11.951

Review 4.  Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.

Authors:  Tilo Freiwald; Behdad Afzali
Journal:  Adv Immunol       Date:  2021-11-19       Impact factor: 3.543

Review 5.  Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient.

Authors:  Miriam Manook; Jean Kwun; Steven Sacks; Anthony Dorling; Nizam Mamode; Stuart Knechtle
Journal:  Transplant Rev (Orlando)       Date:  2018-02-10       Impact factor: 3.943

Review 6.  Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection.

Authors:  Carrie L Butler; Nicole M Valenzuela; Kimberly A Thomas; Elaine F Reed
Journal:  J Immunol Res       Date:  2017-03-08       Impact factor: 4.818

Review 7.  Transplant glomerulopathy: the interaction of HLA antibodies and endothelium.

Authors:  William Hanf; Claudine S Bonder; P Toby H Coates
Journal:  J Immunol Res       Date:  2014-03-09       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.